These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 8625367)
1. Preparation and functional evaluation of new doxorubicin immunoconjugates containing an acid-sensitive linker on small-cell lung cancer cells. Froesch BA; Stahel RA; Zangemeister-Wittke U Cancer Immunol Immunother; 1996 Jan; 42(1):55-63. PubMed ID: 8625367 [TBL] [Abstract][Full Text] [Related]
2. Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates. Trail PA; Willner D; Knipe J; Henderson AJ; Lasch SJ; Zoeckler ME; TrailSmith MD; Doyle TW; King HD; Casazza AM; Braslawsky GR; Brown J; Hofstead SJ; Greenfield RS; Firestone RA; Mosure K; Kadow KF; Yang MB; Hellström KE; Hellström I Cancer Res; 1997 Jan; 57(1):100-5. PubMed ID: 8988048 [TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibody 44-3A6 doxorubicin immunoconjugates: comparative in vitro anti-tumor efficacy of different conjugation methods. Sinkule JA; Rosen ST; Radosevich JA Tumour Biol; 1991; 12(4):198-206. PubMed ID: 1651554 [TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: A novel method for increasing the potency of doxorubicin immunoconjugates. King HD; Yurgaitis D; Willner D; Firestone RA; Yang MB; Lasch SJ; Hellström KE; Trail PA Bioconjug Chem; 1999; 10(2):279-88. PubMed ID: 10077478 [TBL] [Abstract][Full Text] [Related]
5. Targeting of human squamous carcinomas by SPA470-doxorubicin immunoconjugates. Hebert C; Norris K; Sauk JJ J Drug Target; 2003 Feb; 11(2):101-7. PubMed ID: 12881196 [TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibody SEN7 recognizes a new epitope on the neural cell adhesion molecule present on small cell lung cancer but not on lymphocytes. Waibel R; Mannhart M; O'Hara CJ; Brocklehurst C; Zangemeister-Wittke U; Schenker T; Lehmann HP; Weber E; Stahel RA Cancer Res; 1993 Jun; 53(12):2840-5. PubMed ID: 7684948 [TBL] [Abstract][Full Text] [Related]
7. Immunotoxins recognising a new epitope on the neural cell adhesion molecule have potent cytotoxic effects against small cell lung cancer. Zangemeister-Wittke U; Collinson AR; Frösch B; Waibel R; Schenker T; Stahel RA Br J Cancer; 1994 Jan; 69(1):32-9. PubMed ID: 7506925 [TBL] [Abstract][Full Text] [Related]
11. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin. Arabi L; Badiee A; Mosaffa F; Jaafari MR J Control Release; 2015 Dec; 220(Pt A):275-286. PubMed ID: 26518722 [TBL] [Abstract][Full Text] [Related]
12. Anti-Sp17 monoclonal antibody-doxorubicin conjugates as molecularly targeted chemotherapy for ovarian carcinoma. Song JX; Li FQ; Cao WL; Jia X; Shi LN; Lu JF; Ma CF; Kong QQ Target Oncol; 2014 Sep; 9(3):263-72. PubMed ID: 23943313 [TBL] [Abstract][Full Text] [Related]
13. (6-Maleimidocaproyl)hydrazone of doxorubicin--a new derivative for the preparation of immunoconjugates of doxorubicin. Willner D; Trail PA; Hofstead SJ; King HD; Lasch SJ; Braslawsky GR; Greenfield RS; Kaneko T; Firestone RA Bioconjug Chem; 1993; 4(6):521-7. PubMed ID: 7508268 [TBL] [Abstract][Full Text] [Related]
14. Modulation of doxorubicin cytotoxicity by ethacrynic acid. Awasthi S; Singhal SS; He N; Chaubey M; Zimniak P; Srivastava SK; Singh SV; Awasthi YC Int J Cancer; 1996 Nov; 68(3):333-9. PubMed ID: 8903475 [TBL] [Abstract][Full Text] [Related]
15. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248). Mosure KW; Henderson AJ; Klunk LJ; Knipe JO Cancer Chemother Pharmacol; 1997; 40(3):251-8. PubMed ID: 9219510 [TBL] [Abstract][Full Text] [Related]
16. Targeting gastrin-releasing peptide receptors on small cell lung cancer cells with a bispecific molecule that activates polyclonal T lymphocytes. Zhou J; Chen J; Zhong R; Mokotoff M; Shultz LD; Ball ED Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2224-31. PubMed ID: 16609038 [TBL] [Abstract][Full Text] [Related]
17. Adriamycin(hydrazone)-antibody conjugates require internalization and intracellular acid hydrolysis for antitumor activity. Braslawsky GR; Kadow K; Knipe J; McGoff K; Edson M; Kaneko T; Greenfield RS Cancer Immunol Immunother; 1991; 33(6):367-74. PubMed ID: 1878890 [TBL] [Abstract][Full Text] [Related]
18. Tumor targeting using anti-her2 immunoliposomes. Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487 [TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibody Po66 uptake by human lung tumours implanted in nude mice: effect of co-administration with doxorubicin. Desrues B; Léna H; Brichory F; Ramée MP; Toujas L; Delaval P; Dazord L Br J Cancer; 1995 Nov; 72(5):1076-82. PubMed ID: 7577450 [TBL] [Abstract][Full Text] [Related]
20. Evaluation in vitro of adriamycin immunoconjugates synthesized using an acid-sensitive hydrazone linker. Greenfield RS; Kaneko T; Daues A; Edson MA; Fitzgerald KA; Olech LJ; Grattan JA; Spitalny GL; Braslawsky GR Cancer Res; 1990 Oct; 50(20):6600-7. PubMed ID: 2208122 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]